
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Anti‑HER2 use in IHC 1+ or 2+ disease
Panel reviews limited data for zanidatamab and T-DXd in low IHC score tumors and cautions on treating non–HER2-driven disease.
Play episode from 11:47
Transcript


